Lista de obras -

A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer

artículo científico publicado en 2016

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib

artículo científico publicado en 2017

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.

artículo científico publicado en 2014

Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy

artículo científico publicado en 2019

An insight into the molecular genetics of a uveal melanoma patient cohort

article

BCL-2 system analysis identifies high-risk colorectal cancer patients.

artículo científico publicado en 2016

BCL2 protein signalling determines acute responses to neoadjuvant chemoradiotherapy in rectal cancer.

artículo científico publicado en 2014

Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.

artículo científico publicado en 2018

Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer

artículo científico publicado en 2020

Frequency, impact and a preclinical study of novel gene family mutations in HER2-positive breast cancer

article

Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

artículo científico publicado en 2020

Genomic profiling of a dedifferentiated mucosal melanoma following exposure to immunotherapy

scientific article published on 01 April 2020

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)

artículo científico publicado en 2018

HER2-family signalling mechanisms, clinical implications and targeting in breast cancer

artículo científico publicado en 2014

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.

artículo científico publicado en 2015

Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples

artículo científico publicado en 2020

Immune effects of bevacizumab: killing two birds with one stone

artículo científico publicado en 2014

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

artículo científico publicado en 2017

Non-invasive genotyping and monitoring of tumor evolution in locally advanced rectal cancer (LARC) patients using circulating tumor DNA (ctDNA)

artículo científico publicado en 2018

Preclinical drug testing and clinical trial planning of palbociclib (CDK4/6 inhibitor) drug combination with a PI3K or MAPK inhibitor for colorectal cancer (CRC)

artículo científico publicado en 2019

Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer

artículo científico publicado en 2020

Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer

artículo científico publicado en 2020

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

artículo científico publicado en 2016

The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study.

artículo científico publicado en 2014

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer

artículo científico publicado en 2016

Use of exhaled breath condensate (EBC) in the diagnosis of SARS-COV-2 (COVID-19)

artículo científico publicado en 2020

Lista de obras de

A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.

Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy

An insight into the molecular genetics of a uveal melanoma patient cohort

BCL-2 system analysis identifies high-risk colorectal cancer patients.

BCL2 protein signalling determines acute responses to neoadjuvant chemoradiotherapy in rectal cancer.

Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.

Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer

Frequency, impact and a preclinical study of novel gene family mutations in HER2-positive breast cancer

Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Genomic profiling of a dedifferentiated mucosal melanoma following exposure to immunotherapy

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)

HER2-family signalling mechanisms, clinical implications and targeting in breast cancer

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.

Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples

Immune effects of bevacizumab: killing two birds with one stone

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

Non-invasive genotyping and monitoring of tumor evolution in locally advanced rectal cancer (LARC) patients using circulating tumor DNA (ctDNA)

Preclinical drug testing and clinical trial planning of palbociclib (CDK4/6 inhibitor) drug combination with a PI3K or MAPK inhibitor for colorectal cancer (CRC)

Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer

Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study.

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer

Use of exhaled breath condensate (EBC) in the diagnosis of SARS-COV-2 (COVID-19)